Novo Nordisk Earnings Continue to Surge on Blockbuster Weight-Loss Drug Demand

Novo Nordisk’s earnings soared by 56% in the third quarter, boosted by blockbuster weight-loss drugs that have quickly made the Danish drugmaker Europe’s most valuable company.

However, the company said it will continue to restrict the supply of lower-strength doses of its Wegovy obesity medicine in the U.S. to safeguard supplies for current patients.